Cargando…

Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure

AIMS: Factors influencing follow‐up referral decisions and their prognostic implications are poorly investigated in patients with heart failure (HF) with reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF) ejection fraction (EF). We assessed (i) the proportion of, (ii) independent predic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindberg, Felix, Lund, Lars H., Benson, Lina, Schrage, Benedikt, Edner, Magnus, Dahlström, Ulf, Linde, Cecilia, Rosano, Giuseppe, Savarese, Gianluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934918/ https://www.ncbi.nlm.nih.gov/pubmed/35170237 http://dx.doi.org/10.1002/ehf2.13848

Ejemplares similares

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
por: Schrage, Benedikt, et al.
Publicado: (2021)

Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality
por: Schrage, Benedikt, et al.
Publicado: (2022)

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
por: Savarese, Gianluigi, et al.
Publicado: (2020)

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
por: D'Amario, Domenico, et al.
Publicado: (2022)

Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register
por: Eriksson, Björn, et al.
Publicado: (2019)

Association between heart failure quality of care and mortality: a population‐based cohort study using nationwide registries
por: Batra, Gorav, et al.
Publicado: (2022)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
por: Janse, Roemer J., et al.
Publicado: (2022)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
por: Shahim, Angiza, et al.
Publicado: (2023)

Predictors of long‐term outcome in heart failure with preserved ejection fraction: a follow‐up from the KaRen study
por: Shahim, Angiza, et al.
Publicado: (2021)

Changing health related quality of life and outcomes in heart failure by age, sex and subtype
por: Lawson, Claire A., et al.
Publicado: (2023)

Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis
por: Savarese, Gianluigi, et al.
Publicado: (2020)

Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis
por: Ferrannini, Giulia, et al.
Publicado: (2022)

A registry‐based algorithm to predict ejection fraction in patients with heart failure
por: Uijl, Alicia, et al.
Publicado: (2020)

Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft-Gault equation in patients with heart failure
por: Szummer, Karolina, et al.
Publicado: (2017)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Global Public Health Burden of Heart Failure: An Updated Review
por: Shahim, Bahira, et al.
Publicado: (2023)

Comorbidities, risk factors and outcomes in patients with heart failure and an ejection fraction of more than or equal to 40% in primary care- and hospital care-based outpatient clinics
por: Eriksson, B., et al.
Publicado: (2018)

Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
por: Kapelios, Chris J, et al.
Publicado: (2023)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

What determines who gets cardiac resynchronization therapy in europe?
por: Gatti, P, et al.
Publicado: (2023)

Prevalence and prognostic impact of kidney disease on heart failure patients
por: Löfman, Ida, et al.
Publicado: (2016)

Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders
por: Cermakova, Pavla, et al.
Publicado: (2015)

Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry
por: Ergatoudes, Constantinos, et al.
Publicado: (2019)

Trends in cause‐specific readmissions in heart failure with preserved vs. reduced and mid‐range ejection fraction
por: Cui, Xiaotong, et al.
Publicado: (2020)

Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry
por: Kapelios, Chris J, et al.
Publicado: (2023)

Up-To-Date Kitchen Specialties
Publicado: (1912)

Intravenous iron infusion in patients with heart failure: a systematic review and study‐level meta‐analysis
por: Salah, Husam M., et al.
Publicado: (2023)

Prognostic impact over time of ischaemic heart disease vs. non‐ischaemic heart disease in heart failure
por: Silverdal, Jonas, et al.
Publicado: (2020)

Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers
por: Bergh, Claes-Håkan, et al.
Publicado: (2010)

Sequential biventricular pacing improves regional contractility, longitudinal function and dyssynchrony in patients with heart failure and prolonged QRS
por: Edner, Magnus, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_tp48lse0rq2re1d7tb67lli1nu